Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 29 results.
User Information
Export Records
  1. 1.   Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy
  2. Weiss, J. M.; Ridnour, L. A.; Back, T.; Hussain, S. P.; He, P. J.; Maciag, A. E.; Keefer, L. K.; Murphy, W. J.; Harris, C. C.; Wink, D. A.; Wiltrout, R. H.
  3. Journal of Experimental Medicine. 2010, Oct 25; 207(11): 2455-2467.
  1. 2.   Coexpression of IL-18 Strongly Attenuates IL-12-Induced Systemic Toxicity through a Rapid Induction of IL-10 without Affecting its Antitumor Capacity
  2. Rodriguez-Galan, M. C.; Reynolds, D.; Correa, S. G.; Iribarren, P.; Watanabe, M.; Young, H. A.
  3. Journal of Immunology. 2009, Jul; 183(1): 740-748.
  1. 3.   Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA+IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques
  2. Halwani, R.; Boyer, J. D.; Yassine-Diab, B.; Haddad, E. K.; Robinson, T. M.; Kumar, S.; Parkinson, R.; Wu, L.; Sidbu, M. K.; Phillipson-Weiner, R.; Pavlakis, G. N.; Felber, B. K.; Lewis, M. G.; Shen, A.; Siliciano, R. F.; Weiner, D. B.; Sekaly, R. P.
  3. Journal of Immunology. 2008 180(12): 7969-7979.
  1. 4.   Immunotherapy of cancer by IL-12-based cytokine combinations
  2. Weiss, J. M.; Subleski, J. J.; Wigginton, J. M.; Wiltrout, R. H.
  3. Expert Opinion on Biological Therapy. 2007, Nov; 7(11): 1705-1721.
  1. 5.   Endogenous IL-12 triggers an antiangiogenic program in melanoma cells
  2. Airoldi, I.; Di Carlo, E.; Cocco, C.; Taverniti, G.; D'Antuono, T.; Ognio, E.; Watanabe, M.; Ribatti, D.; Pistoia, V.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2007, Mar; 104(10): 3996-4001.
  1. 6.   Macaque multimeric soluble CD40 ligand and GITR ligand constructs are immunostimulatory molecules in vitro
  2. Stone, G. W.; Barzee, S.; Snarsky, V.; Spina, C. A.; Lifson, J. D.; Pillai, V. K. B.; Amara, R. R.; Villinger, F.; Kornbluth, R. S.
  3. Clinical and Vaccine Immunology. 2006, Nov; 13(11): 1223-1230.
  1. 7.   IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis
  2. Kullberg, M. C.; Jankovic, D.; Feng, C. G.; Hue, S.; Gorelick, P. L.; McKenzie, B. S.; Cua, D. J.; Powrie, F.; Cheever, A. W.; Maloy, K. J.; Sher, A.
  3. Journal of Experimental Medicine. 2006, Oct; 203(11): 2485-2494.
  1. 8.   A dose sparing effect by plasmid encoded IL-12 adjuvant on a SlVgag-plasmid DNA vaccine in rhesus macaques
  2. Schadeck, E. B.; Sidhu, M.; Egan, M. A.; Chong, S. Y.; Piacente, P.; Masood, A.; Garcia-H, D.; Cappello, S.; Roopch, V.; Megati, S.; Quiroz, J.; Boyer, J. D.; Felber, B. K.; Pavlakis, G. N.; Weiner, D. B.; Eldridge, J. H.; Israel, Z. R.
  3. Vaccine. 2006, May; 24(21): 4677-4687.
  1. 9.   Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma
  2. Khan, T.; Hixon, J. A.; Stauffer, J. K.; Lincoln, E.; Back, T. C.; Brenner, J.; Lockett, S.; Nagashima, K.; Powell, D.; Wigginton, J. M.
  3. Journal of the National Cancer Institute. 2006, FEB 1; 98(3): 190-202.
  1. 10.   Multicolor fluorescence-based approaches for imaging cytokine-induced alterations in the neovascularization, growth, metastasis, and apoptosis of murine neuroblastoma tumors
  2. Stauffer, J. K.; Khan, T.; Salcedo, R.; Hixon, J. A.; Lincoln, E.; Back, T. C.; Wigginton, J. M.
  3. Journal of Immunotherapy. 2006, MAR-APR; 29(2): 151-164.
  1. 11.   Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody
  2. Fuss, I. J.; Becker, C.; Yang, Z. Q.; Groden, C.; Hornung, R. L.; Heller, F.; Neurath, M. F.; Strober, W.; Mannon, P. J.
  3. Inflammatory Bowel Diseases. 2006, JAN; 12(1): 9-15.
  1. 12.   Treatment of mice with IL-12 DNA constructs leads to augmented NK activity in lungs but low IFN-gamma release - Implications for Bordetella pertussis infections following aerosol challenge
  2. Carter, C. R. D.; Dagg, B. M.; Whitmore, K. M.; Keeble, J. R.; Asokanathan, C.; Rodgers, A.; Watanabe, M.; Xing, D.; Walker, K. B.
  3. Cytokine. 2005, MAY 7; 30(3): 100-108.
  1. 13.   Toxicity vs antitumor effects of hydrodynamic IL-12 (interleukin-12) and IL-18 cDNA injections
  2. Rodriguez-Galan, M. C.; Watanabe, M.; Young, H. A.
  3. Faseb Journal. 2005, MAR 7; 19(5, Part 2, Suppl. S): A1406-A1406.
  1. 14.   Recombinant guinea pig tumor necrosis factor alpha stimulates the expression of interleukin-12 and the inhibition of Mycobacterium tuberculosis growth in macrophages
  2. Cho, H.; Lasco, T. M.; Allen, S. S.; Yoshimura, T.; McMurray, D. N.
  3. Infection and Immunity. 2005, MAR; 73(3): 1367-1376.
  1. 15.   IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: Role for CD8(+) T cells
  2. Salcedo, R.; Stauffer, J. K.; Lincoln, E.; Back, T. C.; Hixon, J. A.; Hahn, C.; Shafer-Weaver, K.; Malyguine, A.; Kastelein, R.; Wigginton, J. M.
  3. Journal of Immunology. 2004, DEC 15; 173(12): 7170-7182.
  1. 16.   Anti-interleukin-12 antibody for active Crohn's disease
  2. Mannon, P. J.; Fuss, I. J.; Mayer, L.; Elson, C. O.; Sandborn, W. J.; Present, D.; Dolin, B.; Goodman, N.; Groden, C.; Hornung, R. L.; Quezado, M.; Neurath, M. F.; Salfeld, J.; Veldman, G. M.; Schwertschlag, U.; Strober, W.
  3. New England Journal of Medicine. 2004, NOV 11; 351(20): 2069-2079.
  1. 17.   CD40 ligand dysregulation in HIV infection: HIV glycoprotein 120 inhibits signaling cascades upstream of CD40 ligand transcription
  2. Zhang, R.; Fichtenbaum, C. J.; Hildeman, D. A.; Lifson, J. D.; Chougnet, C.
  3. Journal of Immunology. 2004 172(4): 2678-2686.
  1. 18.   Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib
  2. Sun, K.; Welniak, L. A.; Panoskaltsis-Mortari, A.; O'Shaughnessy, M. J.; Liu, H. Y.; Barao, I.; Riordan, W.; Sitcheran, R.; Wysocki, C.; Serody, J. S.; Blazar, B. R.; Sayers, T. J.; Murphy, W. J.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2004 101(21): 8120-8125.
  1. 19.   Structure and characterization of hamster IL-12 p35 and p40
  2. Maruyama, K.; Takigawa, Y.; Akiyama, Y.; Hojo, T.; Nara-Ashizawa, N.; Cheng, J. Y.; Watanabe, M.; Yamaguchi, K.
  3. Molecular Immunology. 2003 40(6): 319-326.
  1. 20.   Enhanced in vitro stimulation of rhesus macaque dendritic cells for activation of SIV-specific T cell responses
  2. Mehlhop, E.; Villamide, L. A.; Frank, I.; Gettie, A.; Santisteban, C.; Messmer, D.; Ignatius, R.; Lifson, J. D.; Pope, M.
  3. Journal of Immunological Methods. 2002 260(1-2): 219-234.
  1. 21.   IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside
  2. Wigginton, J. M.; Wiltrout, R. H.
  3. Expert Opinion on Biological Therapy. 2002 2(5): 513-524.
  1. 22.   Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2)
  2. Park, J. W.; Gruys, M. E.; McCormick, K.; Lee, J. K.; Subleski, J.; Wigginton, J. M.; Fenton, R. G.; Wang, J. M.; Wiltrout, R. H.
  3. Journal of Immunology. 2001 166(6): 3763-3770.
  1. 23.   Analysis of the costimulatory requirements for generating human virus-specific in vitro T helper and effector responses
  2. Blazevic, V.; Mac Trubey, C.; Shearer, G. M.
  3. Journal of Clinical Immunology. 2001 21(4): 293-302.
  1. 24.   IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy
  2. Wigginton, J. M.; Gruys, E.; Geiselhart, L.; Subleski, J.; Komschlies, K. L.; Park, J. W.; Wiltrout, T. A.; Nagashima, K.; Back, T. C.; Wiltrout, R. H.
  3. Journal of Clinical Investigation. 2001 108(1): 51-62.
  1. 25.   Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes
  2. Lapointe, R.; Toso, J. F.; Butts, C.; Young, H. A.; Hwu, P.
  3. European Journal of Immunology. 2000 30(11): 3291-3298.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel